Pablo
Sarobe Ugarriza
Catedrático de Universidad
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (27)
2024
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort
Science Advances, Vol. 10, Núm. 28
-
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1
2023
-
Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism
Gut
-
Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies
Frontiers in Immunology, Vol. 13
-
Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)
Frontiers in Immunology
-
Mutated trimeric RBD vaccines: a platform against variants of concern
Signal Transduction and Targeted Therapy
2022
-
Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
Frontiers in Immunology, Vol. 13
-
Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
Frontiers in Immunology, Vol. 13
-
Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy
Journal of Hepatology
-
Neoantigens as potential vaccines in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2
-
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
International Journal of Molecular Sciences, Vol. 23, Núm. 4
2021
-
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946
-
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149
-
The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?
Cancers, Vol. 13, Núm. 13
2020
-
Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma
Cancers, Vol. 12, Núm. 11, pp. 1-18
2019
-
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Cancer Immunology, Immunotherapy, Vol. 68, Núm. 3, pp. 379-393
-
When cancer vaccines go viral
Clinical Cancer Research, Vol. 25, Núm. 16, pp. 4871-4873
2018
-
Enhancement of antitumor vaccination by targeting dendritic cell-related IL-10
Frontiers in Immunology
-
The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer
OncoImmunology, Vol. 7, Núm. 4